|
4-HO-MPMI (also known as 4-Hydroxy-''N''-methyl-(α,''N''-trimethylene)tryptamine or lucigenol) is a tryptamine derivative that is a psychedelic drug. It was developed by the team led by David Nichols from Purdue University in the late 1990s. This compound produces hallucinogen-appropriate responding in animal tests with a similar potency to the amphetamine-derived psychedelic DOI, and has two enantiomers, with only the (''R'')-enantiomer being active. The binding affinity for 5-HT2A receptor is 13 +/- 2 nM (Ki ()DOI). It is reported at doses starting at 0.5 mg and 1.0-1.5 mg seem to be psychedelic doses. The duration it is reported between six to eight hours. The effects, still not too documented, are OEV/CEV, sedation and anxiety.〔http://www.hipforums.com/newforums/showthread.php?t=315326〕 ==See also== * 4-HO-pyr-T * 5-MeO-MPMI * 5-MeO-pyr-T * CP-135,807 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「4-HO-MPMI」の詳細全文を読む スポンサード リンク
|